Caramiphen (edisylate)

Caramiphen edisylate (Parpanil edisylate) is an anticholinergic agent with NMDA receptor antagonist activity. Caramiphen edisylate can be used to inhibit diseases related to cholinergic neurotransmission. Caramiphen edisylate exerts its pharmacological effects by blocking cholinergic effects[1].

Product Specifications

CAS Number

[125-86-0]

Product Name Alternative

Parpanil (edisylate)

UNSPSC

12352005

Hazard Statement

H302

Target

IGluR

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=C(C1(CCCC1)C2=CC=CC=C2)OCCN(CC)CC.O=S(O)(CCS(=O)(O)=O)=O.[1/2]

Molecular Formula

C18H27NO2·1/2C2H6O6S2

Molecular Weight

384.39

Precautions

P264-P270-P330-P501

References & Citations

[1]Figueiredo TH, et al. Delayed tezampanel and caramiphen treatment but not midazolam protects against long-term neuropathology after soman exposure. Exp Biol Med (Maywood) . 2023 Apr;248 (7) :612-623.